The Oncology Institute, Inc. (TOI) Stock Grade

About The Oncology Institute, Inc.'s fundamentals

The Oncology Institute is a cancer care facility operator with a $3.3 billion market capitalization that has demonstrated strong revenue expansion at 27.8% year-over-year growth. However, the company is currently unprofitable, posting a net margin of -12.1% in its latest annual statement, which means it is not yet generating bottom-line earnings. The exceptionally high return on equity of 385.5% reflects the company's minimal equity base rather than operational efficiency, indicating a capital structure skewed heavily toward debt. The company does not pay a dividend, consistent with its current loss-making status.